abbreviations ARE = adverse radiation effects; cAVM = cerebral arteriovenous malformation; EE = endovascular embolization; GK = Gamma Knife; LINAC = linear accelerator; MD = maximal dose; OR = obliteration rate; PD = prescription dose; RS = radiosurgery; S-M = Spetzler-Martin; TOI = treatment obliteration interval. obJect The goal of this study was to evaluate advantages, risks, and failures of Gamma Knife radiosurgery (GKRS) in a large series of pediatric and adolescent patients with cerebral arteriovenous malformations (cAVMs) who were followed up for at least 36 months. methods Since February 1993, 100 pediatric and adolescent patients (≤ 18 years of age) with cAVMs have undergone GKRS at the authors' institution and were followed up for at least 36 months. Forty-six patients were boys and 54 were girls; the mean age was 12.8 years (range 3-18 years). Hemorrhage, either alone or combined with seizure, was the clinical onset in 70% of cases. The mean pre-GK cAVM volume was 2.8 ml; 92% of cAVMs were Spetzler-Martin (S-M) Grades I-III. Most lesions (94%) were in eloquent or deep-seated brain regions, according to S-M classification. The parameters for mean and range in treatment planning were prescription isodose 53.8% (40%-90%); prescription dose (PD) 20.2 Gy (9.0-26.4 Gy); maximal dose (MD) 37.8 Gy (18-50 Gy); and number of shots 4.7 (1-17). On the day of GKRS, stereotactic CT or stereotactic MRI and digital subtraction angiography were used. results Obliteration rate (OR) was angiographically documented in 75 of 84 cases (89.3%) after single-session GKRS, with actuarial ORs at 3 and 5 years of 68.0% and 88.1%, respectively. A repeat treatment was performed in 7 patients (6 with obliteration), and 16 patients with cAVMs underwent staged treatment (9 of them were angiographically cured). Thus, the overall OR was 90%, with actuarial ORs at 3, 5, and 8 years of 59.0%, 76.0%, and 85.0%, respectively. Permanent symptomatic GK-related complications were observed in 11% of cases, with surgical removal of enlarged mass seen on post-RS imaging needed in 5 cases. Hemorrhage during the latency period occurred in 9% of patients, but surgical evacuation of the hematoma was required in only 1 patient. One patient died due to rebleeding of a brainstem cAVM. Radiosurgery outcomes varied according to cAVM sizes and doses: volumes ≤ 10 ml and PDs > 16 Gy were significantly associated with higher ORs and lower rates of permanent complication and bleeding during the latency period. conclusions The data from this study reinforce the conclusion that GKRS is a safe and effective treatment for pediatric and adolescent cAVMs, yielding a high OR with minimal permanent severe morbidity and no mortality. The very low frequency of severe hemorrhages during the latency period further encourages a widespread application of RS in such patients. Univariate analysis found that modified RS-based cAVM score, nidus volume, PD, integral dose, S-M grade, and preplanned treatment (the last 2 parameters were also confirmed on multivariate analysis) significantly influenced OR. Lower S-M grades and single-session planned treatments correlated with shorter treatment obliteration interval on univariate analysis. This statistical analysis suggests that a staged radiosurgical treatment should be planned when nidus volume > 10 ml and/or when the recommended PD is ≤ 16 Gy.
C erebral arteriovenous malformations (cAVMs) are the most frequent cause of intracranial hemorrhage in children after infancy 10, 18 accounting for as many as half of all hemorrhagic strokes in the pediatric and adolescent population. 25 These cAVMs more frequently present after hemorrhage than those in adults, 6, 10 and clinical presentation as spontaneous hemorrhage is reported in more than 80% of pediatric cases. 2, 5, 17, 27 Furthermore, children have a higher risk of rebleeding (25% incidence of rebleeding within 5 years from initial hemorrhage) than adults (in whom cumulative rates of mortality and morbidity are presumably greater because of the prolonged risk period), with both higher mortality (24%) and morbidity rates than adults after initial hemorrhage. 1, 11, 18, 25 These young patients are exposed to a 50% combined risk of permanent morbidity and mortality. 8, 25, 41 Therefore, the "gold standard" treatment should be represented by complete surgical removal, with the aim of removing the risk of further, devastating hemorrhagic strokes. However, cAVMs are more frequently located in deep regions or in eloquent brain areas in children and adolescents (up to 70%-90% of the time) than in adults, 14, 24, 25, 27, 42, 44 exposing these younger patients to high morbidity and mortality risks in the event of surgery.
Endovascular embolization (EE) still carries the risks of an invasive technique, and it is uncommon that complete obliteration is achieved when it is used as a single modality of treatment. 5, 7, 42 There is also the concern that revascularization of obliterated vessels, despite its rarity, may occur more frequently in children than in adults. 13, 43 Thus, embolization alone is often unsatisfactory as a single therapeutic strategy for the majority of inoperable vascular malformations. Therefore, taking into account this complicated and challenging management that the neurovascular team is tasked with, the use of a noninvasive treatment tool such as radiosurgery (RS) has become more and more prevalent worldwide.
In the last 2 decades, several studies on the radiosurgical treatment of pediatric and adolescent cAVMs have reported high obliteration rates (ORs) (74%-86%) and very low frequencies of permanent complications (1.1%-5.0%). 5, 14, 17, 19, 25, 28, 29, 39, 40, 42 But considering the young age of such patients, large numbers of observations and very long follow-up times are needed to evaluate some issues related to the radiosurgical treatment of cAVMs, such as the risk of revascularization, the long-term adverse reaction effect, and permanent complication rates. To the best of our knowledge, only a few series of radiosurgically treated cAVMs in pediatric and adolescent patients, with at least 80 observations and at least 36 months of follow-up, have been published. 5, 14, 33, 34, 36, 42 In this retrospective study, the authors describe the advantages, risks, and failures of Gamma Knife RS (GKRS) on 100 pediatric and adolescent patients with cAVMs who were followed up for at least 36 months. To our knowledge, this is one of the largest series of radiosurgically treated cAVMs in patients ≤ 18 years of age with an observation period of this length.
methods

Patient Population
Between February 1993 and April 2014, 8347 patients were treated with GKRS at our institution. Of these patients, 957 had cAVMs and 151 were pediatric and adolescent patients (≤ 18 years of age). In 100 such cases, a follow-up period of at least 36 months was available. Patients' clinical characteristics are summarized in Table 1 . Briefly, the mean age was 12.8 years (range 3-18 years). Most patients were girls (54%). Bleeding, either alone or combined with seizure, represented the clinical onset in 70% of patients. Before RS, EE procedures were undertaken with the aim of reducing the blood-flow rate within the cAVM and the size of the nidus to a volume more suitable for GKRS in 35 patients, whereas microsurgical incomplete cAVM resection was performed in 7 patients (1 combined treatment of EE and surgery). The median cAVM volume before GKRS was 2.8 ml (range 0.06-39.6 ml). According to the modified RS-based cAVM grading system score, 30,31 the cAVMs were grouped as follows: ≤ 1.0 in 76 cases; 1.01-1.5 in 12; 1.51-2.0 in 7; and ≥ 2.01 in 5. Eloquent brain sites, according to the Spetzler-Martin (S-M) definition, 38 were involved in most cases (94%), and 82% of the cAVMs were located in deep-seated areas (i.e., corpus callosum, pineal region, basal ganglia, thalamus, or brainstem). Spetzler-Martin Grades I-III accounted for 92% of the whole series. Of the 100 cAVMs, the number assigned to low-, intermediate-, and high-flow subgroups was very similar. In 67% of cAVMs, the venous drainage was deep. Based on the volume and location, the cAVMs were preplanned for a single (81%) or staged (19%) treatment, either dose staged (15 of 19) or volume staged (4 of 19) .
During the follow-up period, patients usually underwent postoperative MRI, MR angiography, and neurological evaluations. The first was at 6 months and at 12-month intervals thereafter to assess vascular response, identify delayed or late radiation injury and/or edema of the brain, and guide appropriate management. Follow-up angiography was performed when MRI suggested cAVM occlusion, and at 5 years from GK treatment in all other cases. After obliteration was documented by angiogram, patients were advised to have follow-up MRI every 10 years because of the reported risks of recurrence, 13, 18, 43 delayed postradiosurgical adverse effects, 16 and radiation-induced neoplasia. 41 Neurological morbidity was defined as transient or permanent, and the modified Rankin Outcomes Scale 4,31 was used to grade its severity. Any episode of bleeding during the latency period was registered. Followup data were obtained from hospital notes, imaging studies, and relatives and family physicians. Medical records, MR images, and angiography images for all patients were carefully reviewed. This study was reviewed and approved by the local ethics committee.
radiosurgical techniques
Our radiosurgical technique has been described in detail in previous reports. 20, 21, [24] [25] [26] [27] Briefly, the MRI-compatible Leksell Model G stereotactic frame (Elekta Instruments) was applied to the patient's head. Then, neuroradiological localization was routinely performed using stereotactic 2D cerebral angiography or high-resolution magnification subtraction stereotactic angiograms. More recently, 3D rotational stereotactic angiography (with evaluation of the early arterial to late venous phases) has also been used to define the cAVM nidus (target volume) and to determine target coordinates. Angiographic examination was supplemented with stereotactic CT/MRI, with specific algorithms and sequences, to obtain additional information about the 3D shape of the cAVM and the surrounding normal brain structure. Postcontrast 2-mm-thick coronal and axial images and, more recently, 1-mm-isovoxel volumetric images with gadolinium enhancement, 2-mm-thick T2-weighted MR images, and MR angiography sequences were acquired.
Radiosurgical General endotracheal anesthesia was induced in 52% of patients under 14 years of age and in selected cases in older patients. Patients were discharged from the hospital on the day after treatment.
statistical analysis
Obliteration rate curves were calculated using the Kaplan-Meier method. 15 The interval from treatment to permanent complication due to adverse radiation effects (ARE) was evaluated on an actuarial basis from the day of GKRS treatment to the time MRI showed postradiosurgical changes. The significance was calculated using Fisher's exact test.
Univariate statistical analyses were performed on 18 preidentified independent variables to evaluate whether they correlated significantly with the radiosurgical outcomes, defined as OR, treatment obliteration interval (TOI), permanent complications, and bleeding during latency period (dependent variables). Univariate analysis was performed using the independent samples t-test and nonparametric K-sample test on the equality of medians for continuous variables (i.e., age, cAVM volume, PD, integral dose, and brain volume in 12-Gy isodose volume) and Pearson chi-square and Fisher's exact tests for categorical variables (i.e., sex, cAVM clinical onset, pre-GK treatment, anatomical location, hemispheric-corpus callosum-cerebellar vs basal ganglia-thalamus-brainstem, venous drainage, nidus blood flow, critical vs noncritical location, S-M grade, single vs staged treatment, and stereotactic CT vs stereotactic MRI). Subsequently, to test the significance more accurately, regression analyses were performed using a logistic model. On the basis of internationally accepted criteria, p values ≤ 0.05 were considered statistically significant. Statistical analysis was performed using Stata software, version 13.1 (Stata Corp.). Because this was a retrospective, single-center study, the possibility of bias in patient selection cannot be ruled out.
results clinical results
The mean and median follow-up period was 92.0 and 82.2 months, respectively (range 36.4-234.9 months). At the end of the study, 99 patients were still alive. The only death in our series was due to rebleeding of a brainstem cAVM 42.8 months after radiosurgical treatment. The patient was 18 years old at the time of GKRS and died at the age of 22 years.
Among the other 99 patients, 38 with no deficit prior to radiosurgical treatment remained free from symptoms at last follow-up. In 27 patients neurological complaints were stable, and in 22 patients neurological improvements of their clinical conditions were achieved. Symptomatic worsening occurred in 12 cases: 9 due to GK-related ARE, 1 associated with bleeding, and 2 following symptomatic ARE combined with bleeding of incompletely obliterated cAVMs. Of the 11 patients with permanent symptomatic ARE, 8 were a Grade I-II and 3 were a Grade III, according to the Rankin Handicap Scale. 4 
obliteration rate
A single radiosurgical treatment was planned in 81% of cAVMs, with complete obliteration angiographically documented in 72 patients (88.9%). However, 3 of 19 cAVMs with preplanned dose-staged treatment showed disappearance following the first GK procedure. Thus, the overall number of patients in whom the cAVM cure was achieved after a single GK session was 75 of 84 (89.3%) ( Fig. 1) , with an actuarial OR of 68.0% at 3 years and 88.1% at 5 years ( Table 2 ). The median TOI for these 75 patients was 26.9 months.
In the 9 patients with an incompletely obliterated cAVM, a repeat treatment with GK was performed in 7 cases. A cAVM cure was achieved in 6 of these patients (85.7%), with a median TOI (from first radiosurgical treatment to an angiogram demonstrating complete cAVM obliteration) of 78.2 months.
In 16 patients with particularly critically located cAVMs (deep brainstem and basal ganglia) and/or with nidus volume > 10 ml, a radiosurgically staged treatment was scheduled: this was volume staged in 4 cases and dose staged in 12. Complete obliteration occurred in 9 patients (56.3%) ( Table 2) , and the median TOI was 90.3 months.
Finally, the overall OR for the whole series of 100 patients (followed for at least 36 months) was 90%, with a median TOI of 27.4 months ( Table 2 ). The actuarial ORs at 3, 5, and 8 years were 59.0%, 76.0%, and 85.0%, respectively (Fig. 1) .
Permanent complications
Permanent neurological GK-related complications were registered in 11% of cases. The permanent ARE documented by imaging examinations during the follow-up period were radiation necrosis in 8 cases, edema in 2, and delayed cyst formation in 1. The median interval between RS treatment and symptomatic ARE onset was 63.33 months (range 2.8-125.77 months) (Fig. 1) . Permanent ARE appeared after nidus obliteration in 7 of 11 cases: 6 consisted of radia- tion necrosis and 1 consisted of cyst formation. Surgical intervention was needed to remove the mass effect on the surrounding normal brain parenchyma in 5 of 11 patients, resulting in rapid improvement in neurological deficits.
At the end of the study, the final outcomes for the whole series according to the Pollock-Rankin classification 31 were excellent in 80 patients, good in 7, fair in 3, unchanged in 8, and poor in 1. One patient died.
bleeding during the latency Period
Bleeding during the latency period occurred in 9% of patients, with a median interval from GK to hemorrhagic stroke of 42.8 months (range 2.6-71.43 months). Three of 9 patients had new hemorrhages and the other 6 patients had repeat hemorrhages. As reported above, cAVM rebleeding in 1 case led to the death of the patient. Among the other 8 patients, hemorrhage resulted in a permanent neurological worsening in 1 case. In another case, surgical removal of the intracerebral clot was needed to completely resolve the intracranial hypertension syndrome. In the remaining 6 patients, hemorrhagic stroke did not lead to permanent worsening of neurological conditions.
Of the 9 patients with bleeding during the latency period, 2 bled within 3 years after GKRS and 7 bled more than 3 years after GKRS. It is worth noting that 6 of 7 of these later hemorrhagic strokes occurred in patients who underwent a planned staged RS, and in 1 patient the bleeding followed a repeat treatment for incompletely obliterated cAVM. Tables 3 and 4 show a highly significant correlation between the independent variables (nidus volume and PD) and the end points (OR, GK-related permanent complications, and bleeding during the latency period across the whole series). It seems that a clear cutoff appears for both volume and PD. The probability of complete obliteration highly increases, and the risks of symptomatic permanent complications due to ARE and bleeding during the latency period highly decrease, when the nidus volume is ≤ 10 ml and a PD > 16 Gy can be delivered. In cAVMs with nidus volume exceeding 10 ml and when it is not recommended to deliver a PD > 16 Gy (due to a critical location or large nidus volume), the probability that a single-session planned treatment will be unsuccessful appears to be very high. In such pediatric cAVMs, we propose an algorithm (Fig. 2) in which a staged treatment is scheduled.
statistical analysis/Prognostic Factors
When ORs after a single radiosurgical session were taken into consideration, univariate analysis showed a significant correlation with modified RS-based cAVM score, nidus volume, PD, integral dose (Table 5) , S-M grade, and scheduled treatment (Table 6 ). However, multivariate regression analysis confirmed a highly significant correlation for S-M grading (Cox model) and for type of scheduled treatment (probit model) alone (Table 7) . That is, patients with higher S-M grades and preplanned staged treatment have an extremely low probability of cAVM cure after the first radiosurgical procedure. Of 19 pediatric patients with cAVMs in our series for whom a staged treatment was scheduled, 3 patients (15.8%) achieved complete obliteration of nidus after the first GK session only.
For TOI, univariate analysis showed a statistically significant correlation for type of scheduled treatment and for S-M grade (Table 8) . S-M Grades I, II, and III, and single- session planned treatment of cAVMs, seemed to show a shorter TOI. However, these data were not confirmed on regression analysis. Due to the small number of observations, statistical analysis was not applicable to the other end points of the study: ARE-related permanent complications and bleeding during the latency period.
discussion
Stereotactic RS is a well-established treatment for cAVMs in pediatric and adolescent patients. The decision whether to use RS rather than resection is influenced by a number of factors, which include clinical presentation, patient age, natural history risk for AVM, location of AVM in eloquent or deep areas, nidus volume, and patient preference.
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In the last 3 decades, the use of RS in such patients (either alone or included in combined planned management strategies) has progressively increased and spread worldwide. There are numerous publications on the radiosurgical treatment of pediatric cAVMs, with reported ORs usually varying between 62.5% and 82.7% (Table 9) . However, studies with long follow-up observation periods (at least 36 months) and large population sizes (at least 80 observations) are uncommon. 5, 14, 33, 34, 36, 42 In a recent series of 80 pediatric cAVMs with follow-up data after GKRS, Potts et al. 33 reported an OR of 59.0% following the first radiosurgical treatment. This low cure rate was explained by the fact that the authors favored a lower prescription marginal dose (median 17.5 Gy) and tended to treat larger, more complex AVMs with RS and smaller, less complex AVMs with resection. In other large series of pediatric and adolescent patients with long periods of observation, the ORs after a single-session radiosurgical procedure varied between 62.9% and 75%. Additional RS for cAVMs that remained patent despite initial treatment achieved overall ORs of between 62.5% and 82.7%. In our experience also, the overall OR of the whole series was similar to those reported by other studies (90%), but the rate of cured patients following the first radiosurgical treatment was higher (89.3%) than those of others. This difference is due to the fact that this percentage was calculated only on the number of patients who underwent a preplanned single treatment; i.e., patients usually affected with smaller nidus volume and/or less "critical" cAVMs. The actuarial ORs at 4 and 5 years varied between 65% and 86% 17, 44 and 64% and 94%, 2, 14, 36 respectively. We reported an 88.1% actuarial OR at 5 years in the 84 patients who underwent single treatments and 59.0%, 76.0%, and 85.0% actuarial ORs at 3, 5, and 8 years, respectively, for the whole series.
The mean or median TOI reported in several series was about 2 years, in either GK or linear accelerator (LINAC) series. In our experience, the interval from treatment to cure was very similar after the first treatment (median 26.9 months) and across the whole series (median 27.35 months). This time interval is briefer than in older patients. This result is noteworthy because it is well known that cAVMs in pediatric and adolescent patients present a higher radiosensitivity with shorter obliteration interval than in adults. 9, 21, 28, 40 In cases with repeat RS-so-called salvage retreatment-for cAVMs that remained patent despite initial treatment, the TOIs (considered from the first radiosurgical procedure) in our series (median 78.2 months) and in other radiosurgical series (range 61.0-79.0 months) were similar. 5, 14 For permanent ARE-related complications, we registered an 11% worsening of neurological condition, usually of mild severity (8 of 11 cases with Rankin Handicap Scale Grades I-II). 4 In other series, symptomatic permanent complication rates were between 1.9% and 7.7% (Table 9) . In 2 LINAC studies, permanent side effects occurred more frequently, affecting between 13.3% and 17.6% of patients. 22, 45 The risk of bleeding during the latency period generally ranged from 1.3% to 9.1% in most series, including ours (Table 9 ). When higher rates of hemorrhagic stroke following radiosurgical treatment were reported (16.0%-22.7%), 33, 37, 44 it was always in series of patients treated with a low prescription marginal dose, with large nidus volumes, or both. These radiosurgical strategies are associated with longer TOI and lower ORs, thus leaving these patients exposed to a higher risk of bleeding during the latency period and explaining the high rates of intracerebral hemorrhage.
Indeed, several authors reported a strong correlation among treated volume, PDs, and radiosurgical outcomes (defined as OR, TOI, ARE-related permanent complications, and bleeding during the latency period). Potts et al. 33 reported on a series of children with cAVM treated with a relatively low prescription marginal dose. They described angiographic outcomes, rates of posttreatment hemorrhage, other treatment-related adverse events, and functional outcomes. They found that PD is a critical factor associated with OR, posttreatment hemorrhage, and ARE-related complications. In particular, a PD ≥ 18 Gy was associated with an improved OR and provided protection from posttreatment hemorrhage, even if only a partial response was obtained. On the contrary, these authors observed that a low marginal dose minimized overt neuro- logical deficits directly associated with RS, but also resulted in lower ORs and higher rates of posttreatment hemorrhage. Therefore, the authors recommended a prescription marginal dose of ≥ 18 Gy to maximize AVM obliteration and minimize posttreatment hemorrhage. A cutoff of 18 Gy for PD was also reported by Smyth et al. 37 and Zabel-du Bois et al. 44 In these studies, doses delivered to the margin of nidus volume ≥ 18 Gy improved the ORs but also increased the frequency of permanent neurological worsening. 22 Kano et al. 14 and Yeon et al. 43 identified their PD cutoffs as 20 Gy. These studies found that patients treated with marginal doses ≥ 20 Gy showed a statistically significant increase in angiographically documented cure, but there was no correlation with permanent complications and occurrences of bleeding during the latency period. It is interesting to note that for PD levels higher than 20 Gy, no significant improvements of OR rates were reported. Indeed, Dinca et al. 5 described that 3 different cohorts of patients treated with PDs of 25 Gy, 22.5 Gy, and 20 Gy achieved similar OR percentages: 86.31%, 77.75%, and 82.6%, respectively. In their study, TOI did not differ significantly among the 3 PDs, possibly because this range was relatively narrow. They affirmed that there was a somewhat surprising lack of correlation between outcome and radiosurgical dose when the peripheral (therapeutic) dose was between 20 and 25 Gy, at least as far as OR and TOI are concerned.
Relationships between nidus volume and radiosurgical outcomes have also been well documented. Studies by Pan et al. 29 and Reyns et al. 34 identified a cutoff of 10 ml for treated volumes. These studies found that large cAVMs, i.e., > 10 ml according to the International RadioSurgery Association's algorithm, 12 are associated with lower ORs and higher risk of permanent complications. No correlation was found between the volume of cAVM and hemorrhage occurrence during the latency period.
Our data strongly confirm the correlation among nidus volume, PD, and radiosurgical outcomes or end points. We found that when the treated nidus volume is > 10 ml, the OR decreases and the risks of permanent side effects and hemorrhages dramatically increase. The relationship among these variables is highly significant ( Table 3 ). The same is the case for PD. When the dose delivered to the margin of nidus volume was < 16 Gy, the probability of cure decreased and the frequencies of hemorrhage and permanent sequelae achieved worrisome rates ( Table 4) . The relationship between doses < 16 Gy and an increasing rate of permanent complications registered in our series is explained by the observations that in such cases, cAVMs were located in brainstem and basal ganglia, which are regions where PDs < 16 Gy are recommended. Furthermore, we propose an algorithm for the management of these "critical" patients ( Fig. 2) , suggesting that when the nidus volume > 10 ml and/or when the recommended PD is < 16 Gy, a staged radiosurgical treatment be planned.
Finally, several prognostic factors correlating with radiosurgical outcomes have been identified (Table 10) . The most frequently reported are solitary draining vein, smaller AVM target volume (confirmed on multivariate analysis), larger margin dose (confirmed on multivariate analysis), no previous EE (confirmed on multivariate analysis), low RS-based AVM score (≤ 1), lower S-M grade, and age ≤ 12 years for OR; lower S-M grade and larger margin dose (confirmed on multivariate analysis) for TOI; and cAVM in brainstem-thalamus-basal ganglia, higher RS-based AVM score, and larger AVM volume for ARE-related permanent complications. The univariate statistical analysis performed in the present series showed a significant correlation between smaller AVM target volume, larger margin dose, lower S-M grade, integral dose, and type of preplanned treatment (singlesession GKRS) for OR; and lower S-M grade and type of preplanned treatment for TOI. Nevertheless, multivariate analysis confirmed the prognostic role of S-M grade and type of preplanned treatment for OR only.
conclusions
Our results reinforce the conclusion that GKRS is a safe and effective treatment for pediatric and adolescent patients with cAVMs, yielding a high OR with minimal permanent severe morbidity and no mortality. Furthermore, the very low frequency of severe hemorrhages during the latency period further encourages a widespread application of RS in treatment of pediatric and adolescent cAVMs. Univariate analysis found that modified RS-based cAVM score, nidus volume, PD, integral dose, S-M grade, and preplanned treatment (the last 2 also confirmed on multivariate analysis) significantly influenced ORs. S-M Grades I, II, and III, and single-session planned treatment, correlated with shorter TOI on univariate analysis. Finally, our statistical analysis suggests that a staged radiosurgical treatment should be planned when nidus volume > 10 ml and/or when the recommended PD is ≤ 16 Gy.
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